0
0
New Delhi, November 27, 2025 – India’s battle against antimicrobial resistance (AMR) intensifies as superbugs increasingly resist key everyday antibiotics, according to the latest Indian Council of Medical Research (ICMR) report. Released this week, the 2024 Antimicrobial Resistance Research & Surveillance Network (AMRSN) analysis of nearly 100,000 lab-confirmed samples from top hospitals reveals routine drugs failing against bacteria causing urinary tract infections (UTIs), pneumonia, sepsis, and diarrhoeal diseases. This surge threatens patient outcomes and underscores the urgent need for stricter antibiotic stewardship nationwide.
Key Findings from ICMR Surveillance
The ICMR’s AMRSN report, its eighth annual edition, draws from hospital data across India, highlighting dominance of drug-resistant Gram-negative bacteria like Escherichia coli (E. coli), Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. E. coli, responsible for most UTIs, abdominal infections, and bloodstream cases, shows declining susceptibility to potent antibiotics including fluoroquinolones and third-generation cephalosporins. Klebsiella pneumoniae, a leading culprit in pneumonia and sepsis, resists piperacillin-tazobactam in about 75% of cases and carbapenems in the majority, drastically narrowing treatment choices.
In intensive care units (ICUs), resistance reaches critical levels: Acinetobacter baumannii defies meropenem in 91% of samples, compelling clinicians toward riskier combinations with side effects like kidney damage. Bloodstream infections involve drug-resistant Gram-negatives in 72% of instances, while ventilator-associated pneumonia stems mainly from Acinetobacter, Klebsiella, and Pseudomonas—pathogens evading many high-end antibiotics. Diarrhoeal agents like Salmonella typhi resist fluoroquinolones in over 95% of cases, and fungal threats emerge with Candida auris resistant in 10% of isolates and one-third of Aspergillus samples shrugging off amphotericin B.
Expert Commentary on the Crisis
Dr. Rommel Tickoo, Director of Internal Medicine at Max Hospital, Saket, describes the shift as alarming: “Strong antibiotics are failing against infections once treated easily. This signals an urgent public-health challenge that demands tighter control on antibiotic use and stronger infection-prevention measures.”. Dr. Rakesh Gupta, Senior Consultant in Internal Medicine at Indraprastha Apollo Hospitals, adds, “Everyday bacteria are resisting medicines we once relied on. In ICUs, choices are narrowing even further. Rational antibiotic use is no longer optional—it’s essential to preserve what still works.”.
These clinicians, not involved in the ICMR study, emphasize hospital overuse of broad-spectrum drugs as a driver, echoing global warnings from the World Health Organization (WHO) that AMR could claim 10 million lives yearly by 2050 without intervention. In India, where bacterial AMR linked to 300,000–1.04 million deaths in 2019 alone, the stakes are highest globally.
Background and Rising Threat of AMR
Antimicrobial resistance occurs when bacteria, fungi, viruses, or parasites evolve defenses against drugs meant to kill them, often due to overuse, misuse, or poor infection control. India’s ICMR launched AMRSN in 2017 to track patterns via its i-AMRSS platform, covering 55 antibiotics against 116 pathogens from 80 sample types across networked hospitals. The 2024 data builds on prior reports, showing worsening trends despite minor gains like improved E. coli sensitivity to amikacin and some cephalosporins.
Overprescription—fueled by self-medication, lax regulations, and high infection burdens—exacerbates the issue, with common drugs like azithromycin, amoxicillin, and ofloxacin topping misuse lists. Hospital settings amplify spread via catheters, ventilators, and crowded wards, turning treatable ailments into life threats.
Public Health Implications
This resistance erodes India’s healthcare foundation, prolonging hospital stays, spiking costs, and raising mortality—especially for vulnerable groups like ICU patients and those with chronic conditions. Everyday decisions matter: unnecessary antibiotic courses for viral colds hasten superbug evolution, while hygiene lapses in communities fuel hospital strains.
For patients, implications include delayed recovery from routine UTIs or pneumonia, potentially leading to sepsis. Healthcare workers face dilemmas prescribing “last-resort” drugs with toxicity risks, straining resources in underfunded systems. Nationally, India’s National Action Plan on AMR pushes surveillance, rational use, and awareness, but implementation lags.
Limitations and Counterpoints
The ICMR clarifies its focus on hospital-acquired infections, not community ones, so patterns may not mirror outpatient trends. Some resistance plateaus or dips offer hope, signaling stewardship potential, yet experts caution against complacency amid overall decline. Critics note surveillance gaps in rural areas and self-medication data, urging broader monitoring.
No new antibiotics are pipeline-ready for these superbugs, reinforcing prevention over cure. Diverse viewpoints, including from the Institute for Health Metrics and Evaluation, affirm India’s AMR burden but stress multifaceted solutions beyond hospitals.
Practical Steps for Health Protection
Individuals can act: Complete prescribed courses, avoid over-the-counter antibiotics, and practice handwashing. Healthcare providers should adopt culture-guided therapy and stewardship programs. Policymakers must enforce prescription rules and boost surveillance.
Hospitals can prioritize infection control—like sterile procedures and isolation—to curb spread. Public campaigns, akin to India’s “One Health” approach linking human, animal, and environmental health, hold promise.
References
-
Indian Council of Medical Research (ICMR). Antimicrobial Resistance Research & Surveillance Network (AMRSN): Annual Report 2024. ICMR; 2024. Available at: https://www.icmr.gov.in/icmrobject/uploads/Report/1763981012_icmramrsnannualreport2024.pdf.icmr
